Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 7/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.48 |
| ▸ | F10 | P00742 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037857 | 0.88 | L3MBTL1 (0.51) | NPC1RAB9AHRH3KMT2ALTA4H | |
| SCHEMBL18291424 | 0.85 | KDM4E (0.54) | NPC1RAB9AKDM4EALDH1A1HRH3 | |
| SCHEMBL18291590 | 0.84 | ALDH1A1 (0.56) | NPC1RAB9AKDM4EALDH1A1HRH3 | |
| SCHEMBL20037837 | 0.83 | LTA4H (0.49) | NPC1ALDH1A1KMT2ALTA4H | |
| SCHEMBL20255437 | 0.83 | S1PR5 (0.54) | KMT2ALTA4H | |
| SCHEMBL18291538 | 0.81 | RAB9A (0.52) | NPC1RAB9AKDM4EALDH1A1HRH3 | |
| SCHEMBL18291452 | 0.81 | KMT2A (0.46) | ALDH1A1HRH3KMT2A | |
| SCHEMBL21267595 | 0.81 | KDM4E (0.53) | NPC1RAB9AKDM4EALDH1A1HRH3 | |
| SCHEMBL20249113 | 0.81 | ALDH1A1 (0.53) | NPC1RAB9AKDM4EALDH1A1HRH3 | |
| SCHEMBL20038097 | 0.80 | HRH3 (0.46) | HRH3KMT2ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | TEIJIN PHARMA LIMITED (JP) | 2018-06-14 | — | — | US | disclosed |
| EP-3305785-A1 | PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | Teijin Pharma Limited (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180161329-A1 | PYRIDO[3,4-D]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | CDK4, CDK6, CDK16 | NPC1 3302/4885RAB9A 2154/4885KDM4E 470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.